Aromatase inhibitors better than tamoxifen at reducing the risk of breast cancer recurrence in women

breast cancer
Credit: Unsplash/CC0 Public Domain

A new study has shown that giving aromatase inhibitors instead of tamoxifen to premenopausal women with estrogen receptor positive (hormone-sensitive) breast cancer significantly reduces the risk of breast cancer recurrence. The results have been published today in The Lancet Oncology.

For women with hormone-sensitive, operable , giving treatment after surgery reduces the risk of dying from within 15 years by about one third. Aromatase inhibitors, drugs which block estrogen production, are even more effective than tamoxifen in , reducing this risk by a further 30%.

For , however, aromatase inhibitors are ineffective, since the ovaries respond by increasing estrogen production. However, this problem may be overcome by using treatments that suppress ovarian function, such as drug therapies or surgery. But until now, it was unclear whether aromatase inhibitors or tamoxifen were the most for premenopausal women in reducing breast cancer recurrence.

Researchers from the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), based at Oxford Population Health (University of Oxford) and primarily funded by Cancer Research UK, combined all the available evidence to answer this question, since data from individual trials had been inconclusive. They combined data from four large-scale randomized controlled trials, which involved a total of over 7,000 women with early stage breast cancer, from countries across the world.

Each woman had received an ovarian suppressing treatment. In addition, they were randomly allocated to take an aromatase inhibitor or tamoxifen for three or five years. Over a median follow-up period of eight years, the researchers looked for differences between the two groups in breast cancer recurrence, and deaths from breast cancer or any cause.

Key results:

  • Of the total study population, 888 (12.6%) of the women had a breast cancer recurrence. 418 deaths occurred, of which 54 were from causes unrelated to breast cancer.

In women receiving ovarian suppression therapy:

  • Breast cancer recurrence was significantly reduced in the group who had received aromatase inhibitors instead of tamoxifen. Overall, the risk was reduced by an average of a fifth (21%).
  • The main benefit was seen in the first five years, when the treatments differed, where the risk of recurrence was a third (32%) lower in the aromatase inhibitor group. The absolute reduction in the risk of recurrence was 3.2%: 6.9% in the aromatase inhibitor group versus 10.1% in the tamoxifen group.
  • There was no further benefit, or loss of benefit, between five to ten years.
  • Aromatase inhibitors were just as effective in women aged under 35, who have a higher risk of recurrence than older women.
  • There was no apparent difference in the number of deaths from breast cancer or any cause; however survival benefits from aromatase inhibitors may become apparent after a longer period of follow-up.

Known side effects of aromatase inhibitors include an increased risk of osteoporosis, which can cause . In the analysis, a slightly higher proportion of women in the aromatase inhibitor group had a bone fracture over the follow-up period, compared with the tamoxifen group: 6.4% vs 5.1%. However, the frequency of bone fractures was low overall, and this can be mitigated through treatment with drugs that help to strengthen bones (bisphosphonates).

Tamoxifen can increase the risk of endometrial abnormalities, including uterine polyps and endometrial cancers. In this analysis, the five-year incidence of endometrial cancer was higher in the tamoxifen group (0.3%) compared with the aromatase inhibitor group (0.2%), but still rare overall.

Lead author, Rosie Bradley from Oxford Population Health says that their “aim was to find out whether premenopausal women treated with ovarian suppression could benefit more from aromatase inhibitors than tamoxifen, and these findings conclusively show this is the case for preventing breast cancer recurrence.”

“However, we need to follow patients for longer to find out whether breast cancer deaths are also reduced. Effects on quality of life need to be considered as well, and it is important that clinicians discuss with patients the and risks for each treatment approach.”

Caroline Geraghty, specialist cancer information nurse at Cancer Research UK, says that “this finding has the potential to make a difference in the lives of thousands of women. Most breast cancers are hormone sensitive and treated with hormone therapy. Though there is potential for some side effects, aromatase inhibitors could increase the chance of these women remaining disease free—allowing them to return to normal life.”

“Breast cancer recurrence is especially problematic in younger women, so it’s great news to see that the use of aromatase inhibitors is just as effective in under the age of 35. We look forward to seeing the results of longer-term follow ups to see if save lives.”



Citation:
Aromatase inhibitors better than tamoxifen at reducing the risk of breast cancer recurrence in women (2022, February 3)
retrieved 24 February 2022
from https://medicalxpress.com/news/2022-02-aromatase-inhibitors-tamoxifen-breast-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Penile Necrosis After Injecting Cocaine Into Dorsal Vein thumbnail

Penile Necrosis After Injecting Cocaine Into Dorsal Vein

A 35-year-old man presented to the emergency department with extreme pain in his penis and scrotum. He explained that his symptoms started after he injected cocaine into the dorsal vein of his penis 3 days previously, and the pain has been intensifying. He told clinicians that immediately after injecting the cocaine, he experienced severe pain…
Read More
AI-driven eye scans detect signs of Parkinson's disease early on thumbnail

AI-driven eye scans detect signs of Parkinson’s disease early on

Researchers at Moorfields Eye Hospital and the University College London have used artificial intelligence technology to pinpoint markers within eye scans and identify the existence of Parkinson's disease an average of seven years before clinical symptoms manifest. The research, published in Neurology and claimed to be the largest of its kind, suggests the power of
Read More
COVID's back: Here's what to know this fall and winter thumbnail

COVID’s back: Here’s what to know this fall and winter

Credit: Pixabay/CC0 Public Domain As colder weather sets in, COVID rates are once more rising across the Northern Hemisphere, with several new variants on the scene. Here's what you need to know. COVID versus seasonal nasties? The COVID pandemic extracted a terrible toll, with nearly seven million deaths worldwide. But thanks to vaccines, prior immunity
Read More
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes thumbnail

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Not intended for U.S. and UK Media Berlin, June 22, 2023 – Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double blind parallel-group Phase III study to evaluate the efficacy and safety of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D). The primary objective
Read More
Index Of News
Consider making some contribution to keep us going. We are donation based team who works to bring the best content to the readers. Every donation matters.
Donate Now

Subscription Form

Liking our Index Of News so far? Would you like to subscribe to receive news updates daily?

Total
0
Share